The few amputation events recorded limited the capacity to detect effects in participant subgroups and interpreting multiple tests makes interpretation of borderline significant findings difficult (e.g. the interaction of canagliflozin treatment and amputation risk with baseline antithrombotic use).
← all excerpts
Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program.
1
—
—